Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML

H. Wu, C. Hu, A. Wang, E. L. Weisberg, W. Wang, C. Chen, Z. Zhao, K. Yu, J. Liu, J. Wu, A. Nonami, L. Wang, B. Wang, R. M. Stone, S. Liu, J. D. Griffin, J. Liu, Q. Liu

Research output: Contribution to journalLetter

17 Citations (Scopus)
Original languageEnglish
Pages (from-to)754-757
Number of pages4
JournalLeukemia
Volume30
Issue number3
DOIs
Publication statusPublished - Mar 1 2016
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Wu, H., Hu, C., Wang, A., Weisberg, E. L., Wang, W., Chen, C., Zhao, Z., Yu, K., Liu, J., Wu, J., Nonami, A., Wang, L., Wang, B., Stone, R. M., Liu, S., Griffin, J. D., Liu, J., & Liu, Q. (2016). Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML. Leukemia, 30(3), 754-757. https://doi.org/10.1038/leu.2015.175